Therefore, a clinical trial in ovarian cancer patients has been launched, which tests efficacy of the Smac mimetic birinapant in combination with the TRAIL-R2 agonist conatumumab (clinicaltrials.gov). This evidence concerns the gene TNFRSF10B and ovarian cancer.